Codexis, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission, disclosing the departure of Sriram Ryali as the Chief Financial Officer effective September 30, 2024. In light of this change, a Separation and Consulting Agreement was established between Mr. Ryali and the company on October 16, 2024.
The Separation Agreement outlines the entitlement of Mr. Ryali to severance benefits following a qualifying termination of employment as per the terms of his Change of Control Severance Agreement dated January 27, 2023. Additionally, Mr. Ryali is set to receive a bonus equivalent to 75% of his target bonus for the fiscal year of 2024 as recognition for his service.
As per the filing, Codexis, Inc. has fully complied with the signature requirements of the Securities Exchange Act of 1934, with the report being signed on behalf of the company by Georgia Erbez, Chief Financial Officer, on October 22, 2024.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Codexis’s 8K filing here.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
Read More
- Five stocks we like better than Codexis
- Learn Technical Analysis Skills to Master the Stock Market
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- EV Stocks and How to Profit from Them
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Roth IRA Calculator: Calculate Your Potential Returns
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?